venclyxto
abbvie deutschland gmbh co. kg - venetoclax - białaczka, limfocytowa, przewlekła, komórka b - Środki przeciwnowotworowe - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
ventolin 100 mcg/dawkę inh. aerozol inhalacyjny, zawiesina
glaxosmithkline (ireland) limited - salbutamoli sulfas - aerozol inhalacyjny, zawiesina - 100 mcg/dawkę inh.
ventolin 1 mg/ml (0,1%) roztwór do nebulizacji
glaxosmithkline (ireland) limited - salbutamolum - roztwór do nebulizacji - 1 mg/ml (0,1%)
ventolin 2 mg/ml roztwór do nebulizacji
glaxosmithkline (ireland) limited - salbutamolum - roztwór do nebulizacji - 2 mg/ml
ventolin dysk 200 mcg/dawkę inh. proszek do inhalacji
glaxosmithkline (ireland) limited - salbutamoli sulfas - proszek do inhalacji - 200 mcg/dawkę inh.
ventolin 100 mcg/dawkę inh. aerozol inhalacyjny, zawiesina
inpharm sp. z o.o. - salbutamolum - aerozol inhalacyjny, zawiesina - 100 mcg/dawkę inh.
ventolin 2 mg/ml (0,2%) roztwór do nebulizacji
inpharm sp. z o.o. - roztwór do nebulizacji - 2 mg/ml (0,2%)
ventolin 1 mg/ml (0,1%) płyn do inhalacji z nebulizatora
inpharm sp. z o.o. - płyn do inhalacji z nebulizatora - 1 mg/ml (0,1%)
ventolin 2 mg/ml (0,2%) płyn do inhalacji z nebulizatora
ichem sp. z o.o. - płyn do inhalacji z nebulizatora - 2 mg/ml (0,2%)